- Home
- ANGX vs NGNE Comparison
ANGX vs NGNE Comparison
Compare ANGX & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGX | NGNE |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 743.3M | 744.9M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ANGX | NGNE |
|---|---|---|
| Price | $3.40 | $25.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $8.20 | ★ $77.88 |
| AVG Volume (30 Days) | ★ 1.4M | 342.8K |
| Earning Date | 11-10-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $321,558,306.00 | N/A |
| Revenue This Year | $59.48 | N/A |
| Revenue Next Year | $27.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 233.16 | N/A |
| 52 Week Low | $2.05 | $15.93 |
| 52 Week High | $6.75 | $43.66 |
Technical Indicators
Market Signals| Indicator | ANGX | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 34.84 | 47.84 |
| Support Level | $3.00 | $24.88 |
| Resistance Level | $3.40 | $28.47 |
| Average True Range (ATR) | 0.21 | 2.50 |
| MACD | 0.00 | 0.38 |
| Stochastic Oscillator | 6.95 | 35.88 |
Price Performance
Historical ComparisonAbout ANGX Angel Studios Inc.
Angel Studios Inc is an entertainment company known for crowd-funded films and television projects. It enables creators to share projects and engage audiences directly. The platform allows fans to invest in and promote productions, fostering a community-driven approach to content creation.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.